The company said, “Staar’s (STAA) net sales have declined over the last two years. While management is aggressively executing a plan to return to growth in 2026, the fact is that market dynamics result in a significantly lower growth profile – which negatively impacts valuation.” Guidance taken from the company’s presentation outlining that the proposed merger with Alcon (ALC) is in the best interests of Staar and its stockholders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical Announces Proposed Merger with Alcon
- Staar Surgical reports expiration of window shop period under Alcon merger pact
- Yunqi Capital intends to vote against STAAR Surgical sale to Alcon
- Staar Surgical issues letter to stockholders regarding Alcon merger
- STAAR Surgical Announces Merger with Alcon